 |
|
lexatumumab
A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | anti-TRAIL receptor 2 monoclonal antibody HGS-ETR2
monoclonal antibody HGS-ETR2 | | | | Code name: | | HGS-ETR2 | | |
|
|
